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Human aspartyl (asparaginyl) b-hydroxylase (HAAH) is
over-expressed on the surface of cancer cells. It is an
embryonic protein that is demonstrated to be responsible
for cancer etiology: cell proliferation, motility and invasive-
ness. When normal cells are transfected to over-express
HAAH they behave as transformed and when HAAH is
neutralized or its expression is inhibited, cancer cells
regain a normal phenotype. Anti-HAAH antibodies inhibit
cancer cell growth, motility and invasiveness in vitro, and
inhibit tumor growth in vivo. We have developed a novel
anticancer nanoparticle vaccine in which the N-terminal
or C-terminal thirds of HAAH are expressed on l-phage
(200-300 copies). These anticancer vaccines are immuno-
genic and produce high-titer anti-HAAH polyclonal anti-
bodies in mice. The HAAH gene is highly conserved
between mice and humans. In several experiments these
vaccines have demonstrated strong tumor growth inhibi-
tion in animals. We have previously presented these find-
ings in three posters at SITC 2013. More recently, we have
tried to determine the efficacy of these vaccines in a model
of metastatic breast cancer. After preliminary experiments
which showed vaccine-induced inhibition of metastasis to
the lung, we proceeded with the following experiment.
Female mice were separated into three groups (n = 8).
Groups 2 and 3 were immunized with 1010 phage particles
displaying the N-terminal or C-terminal third of human
HAAH, respectively. Group 1 served as the control
group and received the parent l-phage, not displaying
any added protein. Immunizations were performed on
days 1, 8 and 22. Mice were injected with 2x104 breast
cancer cells (4T1, mouse, triple-negative breast cancer
line) subcutaneously into the mammary fat pad on day 15.
To our surprise, some control animals died as early as day
30 of the experiment, only 15 days after tumor cell chal-
lenge. By the end of the third week post cancer cell trans-
plantation (day 36), only 1 of 8 animals in the control
group survived (12.5%) while 5 of 8 (67.5%) and 8 of 8
(100%) remained alive in groups 2 and 3, respectively. No
further deaths occurred out to day 43, after which the
experiment was terminated. The greater efficacy of the
C-terminal vaccine is likely related to the fact that it com-
prises the catalytic domain of HAAH. This unintended
“survival” experiment indicates that this unique nanoparti-
cle formulation overcomes some of the hurdles to cancer
vaccine development.
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